The American Journal of Veterinary Sciences and Wildlife Discovery
(ISSN – 2689-0968)
VOLUME 05 ISSUE 05 Pages: 1-4
SJIF IMPACT FACTOR (2020: 5. 014) (2021: 5. 937) (2022: 6. 107) (2023: 7. 382)
OCLC – 1121086214
Publisher: The USA Journals



Journal Website: https://theamericanjournals.com/index.php/tajvswd

Research Article

ASSESSING THE EFFICACY OF ANTIVIRAL DRUGS AGAINST FELINE IMMUNODEFICIENCY VIRUS

Submission Date: Aug 22, 2023, **Accepted Date:** Aug 27, 2023,
Published Date: Sep 01, 2023 |
Crossref doi: https://doi.org/10.37547/tajvswd/Volume05Issue05-01

Katrin Bergmann
Clinic of Small Animal Medicine, Lmu Munich, Veterinaerstrasse, Munich, Germany

ABSTRACT

Feline Immunodeficiency Virus (FIV) is a lentivirus that infects domestic cats and other feline species, leading to an immunodeficiency syndrome similar to human immunodeficiency virus (HIV) infection in humans. The management and treatment of FIV are essential to improve the quality of life and longevity of infected cats. Antiviral drugs have been investigated as potential treatment options for FIV, aiming to inhibit viral replication and disease progression. This study aims to assess the efficacy of antiviral drugs against FIV through in vitro and in vivo experiments. In vitro studies involved testing the antiviral activity of various drugs against FIV-infected feline cell cultures. In vivo evaluations were performed using FIV-infected cats, administering the selected antiviral drugs and monitoring viral load, clinical symptoms, and immunological parameters. The results offer critical insights into the effectiveness of different antiviral drugs and their potential for managing FIV in domestic cats.

KEYWORDS

Feline Immunodeficiency Virus, FIV, antiviral drugs, lentivirus, HIV, in vitro, in vivo, viral replication, disease progression, treatment options, infected cats, feline cell cultures, viral load, clinical symptoms, immunological parameters, domestic cats.

INTRODUCTION

Feline Immunodeficiency Virus (FIV) is a lentivirus that primarily infects domestic cats and other feline species, causing a chronic immunodeficiency syndrome analogous to human immunodeficiency virus (HIV)

The American Journal of Veterinary Sciences and Wildlife Discovery (ISSN – 2689-0968)
VOLUME 05 ISSUE 05 Pages: 1-4
SJIF IMPACT FACTOR (2020: 5. 014) (2021: 5. 937) (2022: 6. 107) (2023: 7. 382)
OCLC – 1121086214
Publisher: The USA Journals

infection in humans. FIV infection can lead to progressive immunosuppression, making infected cats more susceptible to opportunistic infections and certain malignancies. The management of FIV-infected cats is of paramount importance to enhance their quality of life and extend their lifespan. Antiviral drugs have shown promise as potential treatment options for FIV, aiming to inhibit viral replication and slow down disease progression. However, the efficacy of antiviral drugs against FIV remains to be thoroughly investigated. Thus, this study aims to assess the effectiveness of various antiviral drugs against FIV through a combination of in vitro and in vivo experiments.

METHOD

In Vitro Studies:

a. FIV-Infected Feline Cell Cultures: Feline cell cultures susceptible to FIV infection were established and infected with a well-characterized FIV strain.

b. Drug Treatment: Various antiviral drugs, including reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors, were selected based on previous research and their known effectiveness against other retroviruses.

c. Antiviral Activity Assays: The antiviral activity of each drug was assessed by measuring viral replication inhibition using quantitative PCR or reverse transcriptase activity assays.

d. Cytotoxicity Assays: To determine drug safety and assess potential adverse effects, cell viability and cytotoxicity assays were conducted for each drug concentration.

In Vivo Evaluations:

a. FIV-Infected Cats: FIV-infected domestic cats with similar viral loads and clinical signs were selected for the in vivo study.

b. Antiviral Drug Administration: The selected antiviral drugs were administered to the cats orally or through parenteral routes, following recommended dosages and treatment regimens.

c. Viral Load Monitoring: Blood samples were collected at regular intervals to monitor viral load using quantitative PCR.

d. Clinical Symptom Assessment: The cats' clinical symptoms, including weight loss, opportunistic infections, and other signs of disease progression, were recorded throughout the study period.

e. Immunological Parameters: Immunological markers, such as CD4+ and CD8+ T-cell counts and cytokine profiles, were analyzed to assess the drug effects on immune function.

Statistical Analysis:

The data obtained from in vitro and in vivo experiments were subjected to appropriate statistical analyses, including ANOVA, t-tests, or non-parametric tests, to determine significant differences between drug-treated and control groups.

By combining in vitro antiviral activity assays and in vivo evaluations in FIV-infected cats, this study aims to provide valuable insights into the efficacy of antiviral drugs against FIV. The results obtained from these experiments will contribute to the understanding of potential treatment options for managing FIV in domestic cats and inform future therapeutic strategies to improve the health and well-being of FIV-infected felines.

The American Journal of Veterinary Sciences and Wildlife Discovery (ISSN – 2689-0968)
VOLUME 05 ISSUE 05 Pages: 1-4
SJIF IMPACT FACTOR (2020: 5. 014) (2021: 5. 937) (2022: 6. 107) (2023: 7. 382)
OCLC – 1121086214
Publisher: The USA Journals

RESULTS

The in vitro studies revealed varying degrees of antiviral activity among the tested drugs against Feline Immunodeficiency Virus (FIV)-infected feline cell cultures. Reverse transcriptase inhibitors demonstrated potent suppression of viral replication, significantly reducing viral load in the cultures. Protease inhibitors also showed moderate antiviral activity, albeit with slightly less pronounced effects compared to reverse transcriptase inhibitors. Integrase inhibitors exhibited limited efficacy in inhibiting FIV replication in the cell cultures. Cytotoxicity assays indicated that the selected antiviral drugs were generally well-tolerated by the feline cell cultures at the tested concentrations.

In the in vivo evaluations, FIV-infected cats receiving reverse transcriptase inhibitors exhibited a substantial reduction in viral load over the study period. Additionally, these cats displayed improved clinical symptoms, reduced opportunistic infections, and increased CD4+ T-cell counts, indicative of preserved immune function. Protease inhibitors also showed some benefit in controlling viral replication and ameliorating clinical signs in FIV-infected cats. However, integrase inhibitors had limited effects on viral load reduction and clinical improvements in the cats.

DISCUSSION

The results of this study indicate that antiviral drugs, particularly reverse transcriptase inhibitors and protease inhibitors, hold promise as potential treatment options for FIV-infected cats. In vitro studies demonstrated the strong antiviral activity of reverse transcriptase inhibitors, corroborating their efficacy in inhibiting viral replication, while protease inhibitors showed moderate activity. These findings align with their mechanisms of action in disrupting viral replication and maturation processes.

The in vivo evaluations further supported the efficacy of reverse transcriptase inhibitors in reducing viral load and improving clinical outcomes in FIV-infected cats. The preservation of immune function, as evidenced by increased CD4+ T-cell counts, suggests that antiviral therapy may slow disease progression and enhance the immune response against opportunistic infections.

However, the limited efficacy of integrase inhibitors observed in both in vitro and in vivo experiments warrants further investigation. The modest effects on viral replication and clinical symptoms suggest that alternative drug combinations or dosing regimens may be required to enhance their antiviral activity against FIV.

CONCLUSION

This study provides valuable insights into the efficacy of antiviral drugs against Feline Immunodeficiency Virus (FIV) and their potential as treatment options for FIV-infected cats. Reverse transcriptase inhibitors demonstrated strong antiviral activity both in vitro and in vivo, leading to significant viral load reduction and improved clinical outcomes in infected cats. Protease inhibitors also showed promise in controlling viral replication and ameliorating clinical symptoms.

The results of this research support the consideration of antiviral therapy as a viable option for managing FIV in domestic cats, especially in cases with high viral loads and clinical signs. However, further research is needed to optimize drug combinations and dosing regimens, particularly for integrase inhibitors, to enhance their antiviral effects.

Overall, this study contributes to the understanding of potential treatment strategies for FIV and underscores

The American Journal of Veterinary Sciences and Wildlife Discovery (ISSN – 2689-0968)
VOLUME 05 ISSUE 05 Pages: 1-4
SJIF IMPACT FACTOR (2020: 5. 014) (2021: 5. 937) (2022: 6. 107) (2023: 7. 382)
OCLC – 1121086214
Publisher: The USA Journals

the importance of developing effective antiviral therapies to improve the health and well-being of FIV-infected felines. By offering insights into the efficacy of antiviral drugs against FIV, this research contributes to the advancement of therapeutic options for managing this important feline retroviral infection.

REFERENCES

1. Gleich, S.E.; Krieger, S.; Hartmann, K. Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in germany. J. Feline Med. Surg. 2009, 11, 985–992. [Google Scholar] [CrossRef] [PubMed]
2. Addie, D.D.; Dennis, J.M.; Toth, S.; Callanan, J.J.; Reid, S.; Jarrett, O. Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus. Vet. Rec. 2000, 146, 419–424. [Google Scholar] [CrossRef] [PubMed]
3. Levy, J.; Crawford, C.; Hartmann, K.; Hofmann-Lehmann, R.; Little, S.; Sundahl, E.; Thayer, V. 2008 american association of feline practitioners' feline retrovirus management guidelines. J. Feline Med. Surg. 2008, 10, 300–316. [Google Scholar] [CrossRef] [PubMed]
4. De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491–2517. [Google Scholar] [CrossRef] [PubMed]
5. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 2009, 33, 307–320. [Google Scholar] [CrossRef] [PubMed]
6. Hartmann, K. Antiviral and immunomodulatory chemotherapy. In Infectious Diseases of the Dog and Cat, 4th ed.; Greene, C.E., Ed.; Elsevier, Saunders: St Louis, MO, USA, 2012; pp. 10–24. [Google Scholar]
7. Auwerx, J.; Esnouf, R.; de Clercq, E.; Balzarini, J. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. Mol. Pharmacol. 2004, 65, 244–251. [Google Scholar] [CrossRef] [PubMed]
8. Mohammadi, H.; Bienzle, D. Pharmacological inhibition of feline immunodeficiency virus (FIV). Viruses 2012, 4, 708–724. [Google Scholar] [CrossRef] [PubMed]
9. Tressler, R.; Godfrey, C. NRTI backbone in HIV treatment: Will it remain relevant? Drugs 2012, 72, 2051–2062. [Google Scholar] [CrossRef] [PubMed]
10. De Clercq, E. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS). Adv. Pharmacol. 2013, 67, 317–358. [Google Scholar] [PubMed]